Want to see AU:CGS full AI Analyst Report?
CGS Stock Chart & Stats
AU$2.53
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$2.53
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$1.55 - AU$3.00
Previous CloseN/A
Volume30.50K
Average Volume (3M)355.93K
Market Cap
AU$489.27M
Enterprise ValueAU$323.50M
Total Cash (Recent Filing)AU$34.07M
Total Debt (Recent Filing)AU$716.74K
Price to Earnings (P/E)31.2
Beta0.13
Next Earnings
Aug 18, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend Yield0.88%
Share Statistics
EPS (TTM)0.06
Shares Outstanding169,884,350
10 Day Avg. Volume327,690
30 Day Avg. Volume355,934
Financial Highlights & Ratios
PEG Ratio1.95
Price to Book (P/B)6.26
Price to Sales (P/S)9.00
P/FCF Ratio35.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.43Price Target Upside35.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.08
Revenue Forecast (FY)AU$67.65M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage and a high equity ratio give Cogstate durable financial flexibility. A strong ROE shows effective capital use, supporting sustained investment in tech and delivery capacity, while providing optionality for dividends or buybacks amid trial timing volatility.
Contracted Revenue And BacklogA sizable, growing backlog and multi-year contracted revenue deliver forward visibility for operations and margins. As trial work converts over time, this backlog supports predictable revenue recognition, enabling planned investments and margin recovery over several quarters.
Scalable Channel Partnerships & DiversificationHigh channel-partner contribution scales customer reach without proportionally higher sales cost. Combined with traction in mood/sleep/other neuro indications, this reduces reliance on direct sales, improves commercial efficiency, and supports revenue diversification over the medium term.
Bears Say
Sharp Reported Revenue DeclineA large year-over-year revenue drop materially weakens the top line base and increases execution risk. Recovery depends on conversion timing of contracts and trial activity; persistent timing effects or slower trial starts could delay sustained revenue growth for multiple quarters.
Free Cash Flow WeaknessA halving of free cash flow reduces internal funding for R&D, platform upgrades, and delivery scaling. While operating cash to net income remains positive, prolonged FCF weakness could force tougher capital allocation choices or external financing for strategic investments.
Concentration Risk In Core IndicationMaterial exposure to large Alzheimer’s programs creates episodic revenue swings tied to trial cycles. This structural concentration amplifies volatility in recognition and capacity planning, making sustained revenue stability contingent on diversification into other CNS indications.
Cogstate Ltd News
CGS FAQ
What was Cogstate Ltd’s price range in the past 12 months?
Cogstate Ltd lowest share price was AU$1.55 and its highest was AU$3.00 in the past 12 months.
What is Cogstate Ltd’s market cap?
Cogstate Ltd’s market cap is AU$489.27M.
When is Cogstate Ltd’s upcoming earnings report date?
Cogstate Ltd’s upcoming earnings report date is Aug 18, 2026 which is in 38 days.
How were Cogstate Ltd’s earnings last quarter?
Cogstate Ltd released its earnings results on Feb 18, 2026. The company reported AU$0.037 earnings per share for the quarter, beating the consensus estimate of AU$0.03 by AU$0.007.
Is Cogstate Ltd overvalued?
According to Wall Street analysts Cogstate Ltd’s price is currently Undervalued.
Does Cogstate Ltd pay dividends?
Cogstate Ltd pays a Notavailable dividend of AU$0.02 which represents an annual dividend yield of 0.88%. See more information on Cogstate Ltd dividends here
What is Cogstate Ltd’s EPS estimate?
Cogstate Ltd’s EPS estimate is 0.05.
How many shares outstanding does Cogstate Ltd have?
Cogstate Ltd has 169,884,350 shares outstanding.
What happened to Cogstate Ltd’s price movement after its last earnings report?
Cogstate Ltd reported an EPS of AU$0.037 in its last earnings report, beating expectations of AU$0.03. Following the earnings report the stock price went up 8.716%.
Which hedge fund is a major shareholder of Cogstate Ltd?
Currently, no hedge funds are holding shares in AU:CGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cogstate Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$3.43 (35.38% Upside)
AU$3.43 (35.38% Upside)
Blogger Sentiment
Bullish
AU:CGS Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth AU$10.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
140.24%
12-Months-Change
Fundamentals
Return on Equity
22.19%
Trailing 12-Months
Asset Growth
12.30%
Trailing 12-Months
Company Description
Cogstate Ltd
Melbourne, Australia-based Cogstate Limited, established in 1999, is a neuroscience technology company specializing in computerized cognitive assessments and digital solutions for clinical outcome evaluations. Its comprehensive suite of cognitive services includes project and data management, scientific consulting, statistical analysis, procurement of assessment scales, rater training, and monitoring solutions. The company operates through two distinct divisions. The Clinical Trials segment delivers technology and support services designed to measure the impact of diseases, pharmaceuticals, medical devices, or other interventions on human participants in clinical studies, primarily serving pharmaceutical and biotechnology clients. Concurrently, its Healthcare segment offers Cognigram, a system facilitating regular and standardized testing to assist primary care physicians and hospitals in the early identification of cognitive decline. By June 30, 2022, Cogstate had participated in an estimated 1,800 academic research initiatives.
CGS Company Deck
CGS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and forward visibility: record new trial starts, a 105% jump in sales contracts, solid YoY revenue/backlog growth, expanding channel partnerships, and a healthy cash balance. Short‑term margin pressure and a $0.5M doubtful debt provision were acknowledged, largely driven by deliberate investments in delivery capacity, timing of contract recognition and one‑off adjustments. Management expects margins to recover in H2 as contracted revenue converts and maintains a clear strategy of diversification and technology investment to sustain medium‑term growth.View all AU:CGS earnings summariesCGS Stock 12 Month Forecast
Average Price Target
AU$3.43
▲(35.38% Upside)
Technical Analysis
Tali Digital
―
Opyl Ltd.
―
Beamtree Holdings Ltd
―
Alcidion Group Limited
―
PainChek Ltd
―
Options Prices
Currently, No data available
---